RenaMed Phase II renal failure data

RenaMed (Lincoln, R.I.) said that preliminary data from a Phase II trial of 58 patients with renal failure and multi-organ dysfunction showed a survival rate of 67% for patients receiving its Renal Bio-Replacement Therapy plus conventional therapy of hemofiltration at day 28 compared with 39% for hemofiltration alone. The survival rate at 90 days in the open-label, U.S. trial was 62% for Renal Bio-Replacement Therapy plus hemofiltration compared with 34% for hemofiltration alone. ...